DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
DONANEMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease
Beta amyloid A4 protein disrupting agent
DONANEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1ADB65P1KK
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IZURALIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IZURALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CANTUZUMAB RAVTANSINE
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
Mucin-1 binding agent
CANTUZUMAB RAVTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
RNQ8JQ4R9P
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CDP-860
2
Antibody
Investigational
Unknown
Unknown
Unknown
Platelet-derived growth factor receptor beta inhibitor
CDP-860
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SOLNERSTOTUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SOLNERSTOTUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IBENTATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IBENTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALTUMOMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ALTUMOMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GACOVETUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
GACOVETUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EMPASIPRUBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
EMPASIPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LINCLATAMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LINCLATAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-888
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms
Receptor tyrosine-protein kinase erbB-3 inhibitor
AMG-888
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMOSTOMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
AMOSTOMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUMROTATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LUMROTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REMZISTOTUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
REMZISTOTUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INCLACUMAB
2
Antibody
Investigational
Unknown
Unknown
Peripheral Arterial Disease; Coronary Disease; Myocardial Infarction
P-selectin antagonist
INCLACUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
A6734I702L
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CIZUTAMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CIZUTAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IZELTABART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IZELTABART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TESNATILIMAB
2
Antibody
Investigational
Unknown
Unknown
Alopecia Areata; Crohn Disease
Unknown
TESNATILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
2B860WP9F0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VISUGROMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
VISUGROMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TELISOTUZUMAB ADIZUTECAN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TELISOTUZUMAB ADIZUTECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MATUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
MATUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
MG4M3QB242
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
QAX-576
2
Antibody
Investigational
Unknown
Unknown
Asthma; Crohn Disease; Eosinophilic Esophagitis; Idiopathic Pulmonary Fibrosis; Keloid; Pulmonary Fibrosis; Rhinitis, Allergic, Seasonal; Scleroderma, Systemic
Interleukin-13 inhibitor
QAX-576
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUVAGROBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LUVAGROBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROLISTOBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ROLISTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BUDOPRUTUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BUDOPRUTUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MISITATUG BLIVEDOTIN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
MISITATUG BLIVEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LOFACIMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LOFACIMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SONAVIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SONAVIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BLONTUVETMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BLONTUVETMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EMILTATUG LEDADOTIN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
EMILTATUG LEDADOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
M195
2
Antibody
Investigational
Unknown
Unknown
Unknown
Myeloid cell surface antigen CD33 other
M195
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROVALPITUZUMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ROVALPITUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZALTENIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ZALTENIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MOZISTOBART ZORATOLIMOD
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
MOZISTOBART ZORATOLIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TADOCIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Integrin alpha-IIb/beta-3 antagonist
TADOCIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
R34T642CGV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
31
32
33
34
35
36
37
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA